CTOs on the Move

Regen BioPharma

www.regenbiopharma.com

 
The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Cyagen

Cyagen Biosciences is an emerging and innovative biotechnology company that specializes in custom murine model generation, DNA vector construction and viral packaging services. We also offer a comprehensive catalog of stem cell lines, cell culture reagents and growth factors. Our rapidly expanding services portfolio features VectorBuilder – an online DNA vector construction platform designed to make tedious cloning projects obsolete. Let us provide the knowledge and resources to move your project forward, and get you back to discovery!

RiboCor

RiboCor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United States Biological Corporation

United States Biological Corporation is a Marblehead, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aytu BioScience

Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company`s therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients` redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company`s strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.

SomaGenics

SomaGenics is a Santa Cruz, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.